JAMA· 2016Q1

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

Paul D. Miller, Gary Hattersley, Bente Juel Riis, Gregory C. Williams et al.

854citations
Q1SCImago
2016year

Short summary

Abaloparatide, 80 μg daily, reduced the risk of new vertebral fractures by 57% and nonvertebral fractures over 18 months compared to placebo in postmenopausal women with osteoporosis.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Orthopedics and Sports Medicine

Orthopedics and Sports MedicineMedicine